1. Home
  2. DARE

as of 02-11-2026 4:00pm EST

$1.72
+$0.03
+1.78%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Founded: 2015 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 24.4M IPO Year: N/A
Target Price: $10.00 AVG Volume (30 days): 76.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.82 EPS Growth: N/A
52 Week Low/High: $1.61 - $9.19 Next Earning Date: 03-30-2026
Revenue: N/A Revenue Growth: -99.65%
Revenue Growth (this year): 3843.33% Revenue Growth (next year): 8700.33%
P/E Ratio: N/A Index: N/A
Free Cash Flow: -6845010.0 FCF Growth: N/A

AI-Powered DARE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 79.11%
79.11%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Dare Bioscience Inc. News

DARE Breaking Stock News: Dive into DARE Ticker-Specific Updates for Smart Investing

All DARE News

Share on Social Networks: